COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Bioequivalence Study Between Fluticasone Propionate 100 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 Inhalation Powder/GSK in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03975166
Recruitment Status : Completed
First Posted : June 5, 2019
Last Update Posted : September 10, 2019
Information provided by (Responsible Party):
Respirent Pharmaceuticals Co Ltd.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 25, 2019
Actual Study Completion Date : August 10, 2019